Fractyl Health Inc. has announced the issuance of two new U.S. patents, further reinforcing its leadership in duodenal resurfacing applications. The patents, U.S. Patent No. 12,329,439 and U.S. Patent No. 12,303,185, focus on electrical energy ablation systems for treating tissue, particularly targeting the duodenal mucosa with various energy forms, including thermal and non-thermal electrical energy. These additions to Fractyl's intellectual property portfolio are designed to protect core innovations in metabolic disease treatment and reflect the company's ongoing commitment to advancing gut-targeted therapies.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。